Soooo love the "estimated" math being done here today, sounds encouraging to go along with what appears to be an ongoing confidence from RVX.

Aside from looking at "expected/estimated" placebo rates, and working toward RRR given the patient estimated years and BoM known MACE events ... is there any other data points that are available to RVX for Primary and/or Secondary studies? ... Assuming all cardio data is locked away, other than knowing the number of MACE events and enrollment and sustained patients/years? 

We've touched on Renal and Cognitive data accumulations which could be early hints a few times (I think?!), but I forget though, ... is RVX privy to any prelim data that would/could/should give reason for optimism on those secondary endpoint fronts along the way?

My usual apologies, it seems these things have been discussed previously, just looking for quick input/answers?